Premium
The road more traveled—common pitfalls on the way to a patent
Author(s) -
Tu Sean,
Wu Bruce,
Maebius Steve
Publication year - 2010
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.107
Subject(s) - anticipation (artificial intelligence) , trademark , nanomedicine , engineering ethics , field (mathematics) , political science , medicine , business , engineering , computer science , law , artificial intelligence , chemical engineering , nanoparticle , mathematics , pure mathematics
Drug delivery and diagnostic imaging patents represent an important subset of patents in the field of nananomedicine. In this article we review the most common rejections issued by the U.S. Patent and Trademark Office relating to these technologies. In particular, we found that the most common rejections are anticipation, obviousness and enablement. We also review the most common strategies used to overcome these rejections, which relate to “teaching away” arguments or claim amendment. WIREsNanomed Nanobiotechnol 2011 3 1–4 DOI: 10.1002/wnan.107 This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine